June 17, 2021
PMLiVE
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
The deal could be worth a total of up to $2.3bn, with Shoreline receiving an undisclosed upfront paym... See more »
1,108 Followers on Owler
Inovio
Inovio is a pharmaceutical company that researches, develops and commercializes synthetic vaccines and immune therapies for the treatment of cancer. Read more
President & CEO
Joseph J. Kim
Missing a competitor? Contribute!
CytImmune is seen as one of Inovio's biggest rivals. CytImmune is headquartered in Rockville, Maryland, and was founded in 1988. Like Inovio, CytImmune also works within the Pharmaceuticals sector. CytImmune generates 77% the revenue of Inovio.
Weigh-in!
Help the Owler community know moreTrending News for Inovio and Inovio's Competitors
June 17, 2021
GlobalNewswire
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
LEXINGTON, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology co... See more »
June 18, 2021
NewsFile
CCXI Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Against ChemoCentryx, Inc.
Radnor, Pennsylvania--(Newsfile Corp. - June 18, 2021) - The law firm of Kessler Topaz Meltzer & Chec... See more »
Inovio Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$6.5M
Inovio's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 60.8M. Over the last four quarters, Inovio's revenue has grown by 38.9%. Specifically, in Q1 2021's revenue was $ < 1M; in Q4 2020, it was $5.6M; in Q3 2020, it was $ < 1M; in Q2 2020, Inovio's revenue was $ < 1M.
Inovio Acquisitions
No recent acquisitions found related to Inovio
Inovio Funding History
Since Inovio was founded in 1979, it has participated in 15 rounds of funding. In total Inovio has raised $296.4M. Inovio's last funding round was on Apr 2020 for a total of $1.3M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
Grant
Apr 2020
$1.3M
Coalition for Epidemic Preparedness Innovations
Grant
Mar 2020
$5M
Grant
Jan 2020
$9M
Debt
Dec 2019
$4M
-
Grant
Sep 2019
--
Since Inovio was founded in 1979, it has participated in 15 rounds of funding. In total Inovio has raised $296.4M. Inovio's last funding round was on Apr 2020 for a total of $1.3M
Inovio Investments
FOLLOW STATUS
COMPANY
DESCRIPTION
AMOUNT
INVESTMENT DATE
ROUND
EXIT DATE
Inovio News
May 11, 2021Medical Buyer
Inovio reports first quarter 2021 financial results
INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicine... See more »
May 11, 2021The Business Journals: Philadelphia
Inovio shifts focus to 'huge' global opportunities for its experimental Covid-19 vaccine
The company's stock opened at its lowest price of the year Tuesday.... See more »
April 27, 2021BioSpace
INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after... See more »
April 26, 2021Pharmabiz
INOVIO planning for exUS global phase 3 trial for its Covid19 vaccine candidate, INO4800
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to tre... See more »
April 23, 2021The Business Journals: Philadelphia
Inovio stock plunges after U.S. government pulls funding for late-stage testing of Covid-19 vaccine candidate
The Plymouth Meeting biotechnology company has been working on its potential Covid-19 vaccine since e... See more »
April 23, 2021Markets Insider
Inovio Stock Slumps After Plans To Exclude US For COVID-19 Vaccine Candidate's Global Trial
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares dived in the premarket in reaction to the company's p... See more »
Inovio Press Releases
March 4, 2021StreetInsider
INOVIO to Present at Upcoming Investor Conferences in March
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company fo... See more »
March 1, 2021PR Newswire Asia
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 m... See more »
January 25, 2021PR Newswire
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a bi... See more »
June 26, 2020centralcharts
Inovio Pharmaceuticals, Inc. - INO Stock Chart Technical Analysis for 06-26-2020
News videos - Inovio Pharmaceuticals, Inc. - INO Stock Chart Technical Analysis for 06-26-2020 - Publ... See more »
June 25, 2020PR Newswire
INOVIO Expands Senior Management Team
PLYMOUTH MEETING, Pa., June 25, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has appoi... See more »
May 14, 2020PR Newswire
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
PLYMOUTH MEETING, Pa., May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 perc... See more »
May 12, 2020centralcharts
FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharmaceuticals - INO
INOVIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND IN... See more »
Inovio Videos
Social Media
Inovio Headquarters
660 West Germantown Pike Suite 110
Plymouth Meeting, Pennsylvania19462
1-267-440-4200
Driving Directions »Trending Companies
IN THE NEWS
AstraZeneca | Taat Lifestyle | Hyundai | T-Mobile | Marriott | Thermo Fisher | Noble Energy | Noble Mineral | Dominion | First Financial Bank | RBC | Digital Realty | Android | BD | DECO | CVS Health | Neuralink | Zogenix | Mercury Systems | Mothercare | Boston Scientific | Hibbett | Hocmai | H&R BLOCK | ODFL | Cohen & Steers | Salesforce | AbbVie | Sanderson Farms | Novartis | PNC | Sarasinandpartners | Valero | Dexcom | CME Group | Mohegan Sun | RealMe | Rimba Raya | Gilead | Akamai | Assurant | Aircraft Philipp Group | Elliott Management | Xylem | Pathbreaker Ventures | Global Blue | AIA Chicago | Galaxy ME | Electronic Arts | Cedar
PEOPLE ALSO VIEWED
Roche | Kymab | Organovo | NanoString | MedMen | Daiichi Sankyo | GW Pharmaceuticals | Evofem | Takeda | AstraZeneca | Natera | Citeline | AgroFresh | GenScript | Citeline | Taylor Wimpey | Tech Data | Officechairs.ie | Cin7 | Pro Nature Organic Foods | Atara Biotherapeutics | Genocea | Biorasi | Crest Cellulose | MeiraGTx | SaveRisk | Ziox Mobiles | Servier Laboratories | PLS Financial Services | LoanBaba
Inovio Summary
ABOUT
Overview
Inovio is a pharmaceutical company that researches, develops and commercializes synthetic vaccines and immune therapies for the treatment of cancer. Inovio was founded in 1979. Inovio's headquarters is located in Plymouth Meeting, Pennsylvania, USA 19...
CEO
Inovio's President & CEO, Joseph J. Kim, currently has an approval rating of 68%. Inovio's primary competitors are CytImmune, bluebird bio & Kite Pharma.Website
inovio.comFrequently Asked Questions about Inovio
When was Inovio founded?
Inovio was founded in 1979Who is Inovio's CEO?
Inovio's CEO is Joseph J. KimHow much revenue does Inovio generate?
Inovio generates $6.5M in revenueHow much funding does Inovio have?
Inovio has historically raised $296.4M in fundingWhere is Inovio's headquarters?
Inovio's headquarters is in Plymouth Meeting Pennsylvania, USA
How many employees does Inovio have?
Inovio has 281 employeesWhat sector does Inovio operate in?
Inovio is in Pharmaceuticals, BiotechnologyWho are Inovio's competitors?
Inovio's top competitors are CytImmune, bluebird bio, Kite PharmaWho has Inovio invested in?
Inovio's has invested in companies such as Geneos Therapeutics, Geneos Therapeutics
